Publications by authors named "Ash Bahl"

Claim this Profile
T
Targeting CDK12 disrupts estrogen-receptor chromatin recruitment and ER-MED1 transcription in advanced ER+ breast cancer.
Daniela Ottaviani, Mihaela Ola, Alessandra Allotta, Yasmine Maati Chaibi, Seán Hickey, Ash Bahl

J Natl Cancer Inst· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer.
Theodora A Constantin, Anabel Varela-Carver, Kyle K Greenland, Gilberto Serrano de Almeida, Ellen Olden, Ash K Bahl

Br J Cancer· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-resolution cryo-EM of the human CDK-activating kinase for structure-based drug design.
Victoria I Cushing, Adrian F Koh, Junjie Feng, Kaste Jurgaityte, Alexander Bondke, Ash K Bahl

Nat Commun· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer.
Theodora A Constantin, Anabel Varela-Carver, Kyle K Greenland, Gilberto Serrano de Almeida, Ellen Olden, Ash K Bahl

Br J Cancer· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intratracheal and oral administration of SM-276001: a selective TLR7 agonist, leads to antitumor efficacy in primary and metastatic models of cancer.
Erina Koga-Yamakawa, Simon J Dovedi, Masashi Murata, Hiroyuki Matsui, Andrew J Leishman, Ash Bahl

Int J Cancer· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H₁ antagonists. Part II: optimising in vivo clearance.
Mark Furber, Lilian Alcaraz, Christopher Luckhurst, Ash Bahl, Haydn Beaton

Bioorg Med Chem Lett· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H₁ antagonists. Part I.
Mark Furber, Lilian Alcaraz, Christopher Luckhurst, Ash Bahl, Haydn Beaton

Bioorg Med Chem Lett· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.
Ash Bahl, Patrick Barton, Keith Bowers, Moya V Caffrey, Rebecca Denton

Bioorg Med Chem Lett· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The discovery of CCR3/H1 dual antagonists with reduced hERG risk.
Ash Bahl, Patrick Barton, Keith Bowers, Steven Brough, Richard Evans

Bioorg Med Chem Lett· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of a dual CCR3 and H1-antagonist on symptoms and eosinophilic inflammation in allergic rhinitis.
Lennart Greiff, Cecilia Ahlström-Emanuelsson, Ash Bahl, Thomas Bengtsson, Kerstin Dahlström

Respir Res· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CpG-containing immunostimulatory DNA sequences elicit TNF-alpha-dependent toxicity in rodents but not in humans.
John D Campbell, Yan Cho, Martyn L Foster, Holger Kanzler, Melissa A Kachura, Ash Bahl

J Clin Invest· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Functional analysis of the chemokine receptor CCR3 on airway epithelial cells.
Lisa A Beck, Brian Tancowny, Mary E Brummet, S Yukiko Asaki, Stephanie L Curry, Ash Bahl

J Immunol· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis